Pharmacokinetic properties of new antiepileptic drugs

Journal of Pharmacy Practice

Volumn 18, Issue 6, 2005, Pages 444-460

  Splinter, Michele Y ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Antiepileptic therapy; Drug interactions; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DRUG METABOLITE; ERYTHROMYCIN; ETHINYLESTRADIOL; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SERTRALINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AGE; AGGRESSION; ANOREXIA; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG TOLERABILITY; EPILEPSY; EPOXIDATION; FLATULENCE; FOCAL EPILEPSY; GAS LIQUID CHROMATOGRAPHY; GENDER; GENERALIZED EPILEPSY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; LACTATION; LENNOX GASTAUT SYNDROME; LIVER DISEASE; NEPHROTOXICITY; NEUROTOXICITY; PATIENT COMPLIANCE; PHARMACOKINETICS; PREGNANCY; REVIEW; SIDE EFFECT;

EID: 28244451314     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190005282733     Document Type: Review

References (71)

1. Perucca E. Marketed new antiepileptic drugs: are they better than old-generation agents? Ther Drug Monitor. 2002;24:74-80.
2. Bourgeois BFD. Pharmacokinetic properties of current antiepileptic drugs: what improvements are needed? Neurology. 2000;55:S11-S16.
3. Gidal BE. Pharmacokinetics of the new antiepileptic drugs. Am J Managed Care. 2001;7(Suppl):S216-S220.
4. Glauser TA, Pippenger CE, Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy. Epilepsia. 2000;41(Suppl 8):S6-S15.
5. Arryoyo S, Kramer G. Treating epilepsy in the elderly. Drug Safety. 2001;24:991-1015.
6. Splinter MY. Epilepsy in the female patient: new pharmacotherapy and gender-related issues. Female Patient. 2002;27:
7. (Primary Care Ed) 33-39, (OB/GYN Ed) 32-39.
8. French J. Use of levetiracetam in special populations. Epilepsia. 2001;42(Suppl 4);40-43.
9. Tomson T, Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol. 2000;55:697-705.
10. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25:347-363.
11. Kelley MT, Walson PD, Cox S, Dusci LJ. Population pharmacokinetics of felbamate in children. Ther Drug Monit. 1997;19:29-36.
12. Theodore WH. Felbamate. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippencott-Raven; 1998:1509-1514.
13. Pellock JM. Felbamate. Epilepsia. 1999;40(Suppl 5):S57-S62.
14. Gram L. Pharmacokinetics of new antiepileptic drugs. Epilepsia. 1996;37(Suppl 6):S12-S16.
15. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit. 2002;24:91-103.
16. Glue P, Sulowicz W, Colucci R, et al. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction. Br J Clin Pharmacol. 1997;44:91-93.
17. Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia. 1999;40(Suppl 9):S7-S13.
18. The felbamate study group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med. 1993;328:29-33.
19. Harden CL, Trifiletti R, Kutt H. Felbamate levels in patients with epilepsy. Epilepsia. 1996;37:280-283.
20. Troupin AS, Montouris G, Hussein G. Felbamate: therapeutic range and other kinetic information. J Epilepsy. 1997;10:26-31.
21. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet. 2000;38:191-204.
22. Morris GL. Gabapentin. Epilepsia. 1999;40(Suppl 5):S63-S70.
23. Haig GM, Bockbrader HN, Wesche DL, et al. Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. J Clin Pharmacol. 2001;41:507-514.
24. Goa KL, Sorkin EM. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993;43:409-427.
25. Ouellet D, Bockbrader HN, Wesche DL, Shapiro DY, Garofalo E. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res. 2001;47:229-241.
26. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology. 1994;44(Suppl 5):S17-S22.
27. Berry DJ, Beran RG, Plunkeft MJ, Clarke LA, Hung WT. The absorption of gabapentin following high dose escalation. Seizure. 2003;12:28-36.
28. Boyd RA, Türck D, Abel RB, Sedman AJ, Bockbrader HN. Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia. 1999;40:474-479.
29. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000;40:123-127.
30. Wilson EA, Sills GJ, Forrest G, Brodie MJ. High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. Epilepsy Res. 1998;29:161-166.
31. Muscas GC, Chiroli S, Luceri F, Del Mastio, M, Balestrieri F, Arnetoli G. Conversion from thrice daily to twice daily administration of gabapentin (GBP) in partial epilepsy: analysis of clinical efficacy and plasma levels. Seizure. 2000;9:47-50.
32. Chan V, Morris RG, Ilett K, Tett SE. Population pharmacokinetics of lamotrigine. Ther Drug Monit. 2001;23:630-635.
33. GlaxoSmithKline. Lamictal package insert. Research Triangle Park, NC: GlaxoSmithKline; 2003.
34. Birnbaum AK, Kriel RL, Im Y, Remmel RP. Relative bioavailability of lamotrigine chewable dispersible tablets administered rectally. Pharmacotherapy. 2001;21:158-162.
35. Armijo JA, Bravo J, Cuadrado A, Herranz JL. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit. 1999;21:182-190.
36. Chen C. Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children. Br J Clin Pharmacol. 2000;50:135-145.
37. Tran TA, Leppick IE, Blesi K, Sathanandan ST, Remmel R. Lamotrigine clearance during pregnancy. Neurology. 2002;59:251-255.
38. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate and during lactation. Epilepsia. 2000;41:709-713.
39. Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol. 1998;46:547-551.
40. Böttiger Y, Svensson JO, Ståhle L. Lamotrigine drug interactions in a TDM material. Ther Drug Monit. 1999;21:171-174.
41. Chong E, Dupuis LL. Therapeutic drug monitoring of lamotrigine. Ann Pharmacother. 2002;36:917-919.
42. Shorvon SD, van Rijckevorsel K. A new antiepileptic drug: levetiracetam, a pyrrolidone recently licensed as an antiepileptic drug. J Neurol Neurosurg Psychiatry. 2002;72:426-429.
43. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia. 2001;42(Suppl4):24-27.
44. Wheless JW. Using the new antiepilepsy drugs in children. J Child Neurol. 2002;17(Suppl 1):S58-S64.
45. Pellock JM, Glauser TA, Bebin EM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia. 2001;42:1574-1579.
46. Leppik I, Morrell M, Godfroid P, Arrigo C. Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy. Epilepsia. 2003;44:1350-1352.
47. Gram L. Oxcarbazepine. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippencott-Raven; 1998;1541-1546.
48. Beydoun A, Kutluay E. Oxcarbazepine. Exper Opin Pharmacother. 2002;3:59-71.
49. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand. 1993;87:224-227.
50. Schachter SC. Tiagabine. Epilepsia. 1999;40(Suppl 5):S17-S22.
51. Abbott Laboratories. Gabitril package insert. North Chicago, IL: Abbott Laboratories; 1999.
52. Samara EE, Gustavson LE, Shourbagy TE, Locke C, Granneman GR, Sommerville KW. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy. Epilepsia. 1998;39:868-873.
53. Pellock JM. Tiagabine (Gabitril) experience in children. Epilepsia. 2001;42(Suppl 3):49-51.
54. Sommerville KW. Tiagabine. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippencott-Raven; 1998:1645-1653.
55. Wang PWS, Ketter TA. Pharmacokinetics of mood stabilizers and new anticonvulsants. Psychopharmacol Bull. 2002;36:44-66.
56. Williams J, Bialer M, Johannessen SI, et al. Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia. 2003;44:40-45.
57. Ortho-McNeil Pharmaceutical. Topamax approved labeling text dated 6/29/05. Raritan, NJ: Ortho-McNeil Pharmaceutical; Retrieved October 10, 2005, from www.fda.gov/cder/foi/label/ 2005/020505s018lbl.pdf.
58. Glauser TA. Topiramate. Epilepsia. 1999;40(Suppl 5):S71-S80.
59. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia. 2000;41(Suppl 1):S61-S65.
60. Christensen J, Højskov CS, Dam M, Poulsen JH. Plasma concentration of topiramate correlates with cerebrospinal fluid concentration. Ther Drug Monit. 2001;23:529-535.
61. Rosenfeld WE, Doose DR, Walker SA, Baldassarre JS, Reife RA. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol. 1999;20:339-344.
62. Glauser TA, Miles MV, Tang P, Clark P, McGee K, Doose DR. Topiramate pharmacokinetics in infants. Epilepsia. 1999;40: 788-791.
63. Sachdeo RC, Sachdeo SK, Levey RH, et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia. 2002;43:691-696.
64. Doose DR, Brodie MJ, Wilson EA, et al. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia. 2003;44:917-922.
65. May TW, Rambeck B, Jürgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age and comedication. Ther Drug Monit. 2002;24:366-374.
66. Seino M, Ito T. Zonisamide. In: Engel J Jr, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippencott-Raven; 1998;1621-1622.
67. Willmore LJ. Clinical pharmacology of new antiepileptic drugs. Neurology. 2000;55(Suppl 3):S17-S24.
68. Leppik IE. Zonisamide. Epilepsia. 1999;40(Suppl 5):S23-S29.
69. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit. 1998;20:593-597.
70. Elan Biopharmaceuticals. Zonegran package insert. San Diego, CA: Elan Biopharmaceuticals; 2003.
71. Gidal BE, Garnett WR, Graves N. Epilepsy. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. New York: McGraw-Hill; 2002:1031-1059.